Tel Aviv, Israel – September 18, 2026 -- Lutris Pharma will present updated phase 2 clinical data for its topical B-Raf inhibitor LUT014 at the 35th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, running September 30 through October 3.
Oral presentation scheduled for October 2 at EADV Congress in Vienna
The randomized, double-blind, placebo-controlled trial results will be delivered in an oral presentation titled 'Acneiform Rash from EGFR Inhibitor Therapy: Durable, Mechanism-Directed Reduction with Topical LUT014 (B-Raf Inhibitor) in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.' The session, Free Communication 6: Pruritus/Adverse Drug Reactions, is set for Friday, October 2, 2026, from 11:25 to 11:35 am CET in Hall N. Anisha Patel, MD, professor of Dermatology at The University of Texas MD Anderson Cancer Center in Houston, will present the data under Abstract ID AS-1328.
LUT014 targets a widespread side effect of EGFR inhibitor cancer therapy
LUT014 is a first-in-class, small molecule topical B-Raf inhibitor formulated as a gel and applied directly to affected skin. EGFR inhibitors, used to treat cancers including colorectal, lung, head and neck, urinary bladder, pancreatic and breast cancers, block MAPK pathway signaling to shrink tumors but cause dermatological toxicities in most patients, typically presenting as papulopustular acneiform rash. This side effect can compromise quality of life and reduce adherence to anti-cancer therapy.
Compound exploits paradoxical MAPK reactivation to spare skin cells
LUT014 leverages the paradoxical effect of B-Raf inhibitors: when a MAPK inhibitor acting upstream of B-Raf, such as an EGFR or RAS inhibitor, shuts down pathway signaling, both cancerous and normal cells die. Inhibiting B-Raf in these already-suppressed cells reactivates MAPK signaling, rescuing non-cancerous skin cells while leaving anti-tumor activity unaffected. Due to overwhelmingly local skin penetration, the company states LUT014's activity remains restricted to the treated area. The compound previously demonstrated favorable safety and clinical benefit in a completed phase 2 trial in metastatic colorectal cancer patients with EGFR inhibitor-induced acneiform lesions.